Graft Charges At India State Drug Controller’s Office Lead To Multiple Transfers
This article was originally published in PharmAsia News
As news of fresh corruption charges cloud efforts for transparency in India’s licensing process, several high-profile officials are learned to have been moved in a brisk clean-up exercise by the health ministry.
You may also be interested in...
MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.